MEDP vs. QGEN: Medpace vs. Qiagen Stock Comparison
How do Medpace (MEDP) and Qiagen (QGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Medpace (MEDP) and Qiagen (QGEN) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | MEDP | QGEN |
|---|---|---|
| Name | Medpace Holdings, Inc. | Qiagen N.V. |
| Country/Region | United States | Netherlands |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 18.27 billion USD | 10.39 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | August 11, 2016 | June 28, 1996 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | MEDP | QGEN |
|---|---|---|
| Total Return (1Y) | 13.29% | 17.09% |
| Total Return (3Y, Annualized) | 35.26% | 10.44% |
| Total Return (5Y, Annualized) | 24.49% | -0.72% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | MEDP | QGEN |
|---|---|---|
| Volatility (1Y, Annualized) | 44.16% | 35.52% |
| Beta (5Y) | 1.10 | 0.56 |
| Max Drawdown (5Y) | -42.87% | -41.97% |
| Avg. Volume (3M) | 258.39K | 3.68M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | MEDP | QGEN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.20 | 0.36 |
| Sortino Ratio (1Y) | 0.26 | 0.60 |
Profitability
ROE (TTM)
Both companies show strong equity returns, but Medpace (MEDP) at 117.88% is the standout with ROE above its industry range; Qiagen (QGEN) at 10.81% also sits in the top quartile.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
117.88%
- MEDP
- 117.88%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.81%
- Max
- 109.18%
- QGEN
- 10.81%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Medpace (MEDP) at 18.24% and Qiagen (QGEN) at 18.20% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.24%
- MEDP
- 18.24%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.20%
- QGEN
- 18.20%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Medpace (MEDP) at 23.12% and Qiagen (QGEN) at 27.75% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.12%
- Max
- 83.12%
- MEDP
- 23.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.75%
- Max
- 83.12%
- QGEN
- 27.75%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | MEDP | QGEN |
|---|---|---|
| ROE (TTM) | 117.88% | 10.81% |
| ROA (TTM) | 18.71% | 5.68% |
| Net Margin (TTM) | 18.24% | 18.20% |
| Operating Margin (TTM) | 23.12% | 27.75% |
| Gross Margin (TTM) | 72.24% | 67.06% |
Growth
Revenue Growth
Both Medpace (MEDP) at 19.97% and Qiagen (QGEN) at 5.65% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Qiagen (QGEN) at 409.76% clears its industry range for EPS growth, a much stronger earnings trajectory than Medpace (MEDP) at 20.98%, which is closer to a typical peer reading.
Growth Metrics
| Metric | MEDP | QGEN |
|---|---|---|
| Revenue Growth (YoY) | 19.97% | 5.65% |
| Revenue Growth (3Y CAGR) | 20.12% | -0.81% |
| EPS Growth (YoY) | 20.98% | 409.76% |
| EPS Growth (3Y CAGR) | 28.04% | -0.19% |
Financial Strength
Current Ratio (MRQ)
Qiagen (QGEN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Medpace (MEDP) at 0.83 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MEDP.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MEDP
- 0.83
- Min
- 0.10
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.63
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- QGEN
- 2.63
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Medpace (MEDP) at 0.29 and Qiagen (QGEN) at 0.47 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.29
- Max
- 1.42
- Q3
- 0.65
- MEDP
- 0.29
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.47
- Max
- 1.42
- Q3
- 0.65
- QGEN
- 0.47
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | MEDP | QGEN |
|---|---|---|
| Current Ratio (MRQ) | 0.83 | 2.63 |
| Debt / Equity (MRQ) | 0.29 | 0.47 |
| Net Debt / EBITDA | -0.84 | 1.08 |
Dividends
Dividend Yield (TTM)
Medpace (MEDP) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a yield of 0.71%, ranking against industry peers normally.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MEDP
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.71%
- QGEN
- 0.71%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Medpace (MEDP) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a payout of 18.21%, ranking against industry peers normally.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MEDP
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.21%
- QGEN
- 18.21%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | MEDP | QGEN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.71% |
| Dividend Payout Ratio (TTM) | 0.00% | 18.21% |
Valuation
P/E Ratio (TTM)
Both Medpace (MEDP) at 36.26 and Qiagen (QGEN) at 27.21 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.26
- Max
- 85.34
- Q3
- 43.46
- MEDP
- 36.26
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.21
- Max
- 85.34
- Q3
- 43.46
- QGEN
- 27.21
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Medpace (MEDP) at 6.44 and Qiagen (QGEN) at 4.91 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.44
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- MEDP
- 6.44
- Q1
- 3.01
- Min
- 0.01
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.91
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- QGEN
- 4.91
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Qiagen (QGEN) at 2.99 sits near its industry’s typical P/B ratio, while Medpace (MEDP) at 31.23 prices above its benchmark range — MEDP looks rich relative to book.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.23
- MEDP
- 31.23
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.99
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- QGEN
- 2.99
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | MEDP | QGEN |
|---|---|---|
| P/E Ratio (TTM) | 36.26 | 27.21 |
| P/S Ratio (TTM) | 6.44 | 4.91 |
| P/B Ratio (MRQ) | 31.23 | 2.99 |
| Free Cash Flow Yield (TTM) | 2.72% | 3.62% |